ERBB2 and breast cancer: Moreover, all breast cancers with ESR1 mutations were invasive ductal carcinomas, with a majority of luminal B subtype (75.0%, 12/16) and the remaining four patients had HER2-enriched (n=2) and triple-negative (n=2) subtypes.